AstraZeneca Joins the In-Licensing Game

Much of AstraZeneca's newly-in-licensed bounty is high-risk. But it provides a low-cost pipeline boost, and marks a sharp turnaround at the firm.

By Melanie Senior

AstraZeneca PLC may have come late to the in-licensing game, but it arrived with a flourish in December 2005,...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Business Strategy

More from In Vivo